［1］Chen WQ,H Li,KX Sun,et al.Report of cancer incidence and mortality in China,2014［J］.Chinese Journal of Cancer,2018,40(1):5-13.
［2］Vici P,L Pizzuti,C Natoli,et al.Triple positive breast cancer:A distinct subtype［J］?Cancer Treat Rev,2015,41(2):69-76.
［3］Ellis MJ,Y Tao,O Young,et al.Estrogen-independent proliferation is present in estrogen-receptor HER-2-positive primary breast cancer after neoadjuvant letrozole［J］.J Clin Oncol,2006,24(19):3019-3025.
［4］Anderson WF,PS Rosenberg,A Prat,et al.How many etiological subtypes of breast cancer:Two,three,four,or more［J］?Breast Diseases A Year Book Quarterly,2015,26(4):296-297.
［5］Popovska S,I Ivanov.Lymphatic vascularization in primary breast cancer:HER-2 overexpressing tumors contain more lymphatics than steroid receptor positive,triple-positive and triple negative breast carcinomas［J］.Turk Patoloji Derg,2014,30(2):124-132.
［6］Kast K,T Link,K Friedrich,et al.Impact of breast cancer subtypes and patterns of metastasis on outcome［J］.Breast Cancer Res Treat,2015,150(3):621-629.
［7］Iancu G,D Vasile,RC Iancu,et al."Triple positive" breast cancer - a novel category［J］?Rom J Morphol Embryol,2017,58(1):21-26.
［8］Fedele P,N Calvani,A Marino,et al.Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer:Where are we now and where are we going［J］?Crit Rev Oncol Hematol,2012,84(2):243-251.
［9］Murphy BL,CN Day,TL Hoskin,et al.Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders:Triple-negative and HER-2（+） subtypes［J］.Ann Surg Oncol,2018,25(8):2241-2248.
［10］Darb-Esfahani S,S Loibl,BM Muller,et al.Identification of biology-based breast cancer types with distinct predictive and prognostic features:Role of steroid hormone and HER-2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy［J］.Breast Cancer Res,2009,11(5):R69.
［11］Hurvitz SA,M Martin,WF Symmans,et al.Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1
［K］) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER-2-positive (HER-2+) early breast cancer (EBC) (KRISTINE)［J］.Journal of Clinical Oncology,2016,34(15_suppl):500.
［12］Rimawi M,R Cecchini,P Rastogi,et al.Abstract S3-06:A phase III trial evaluating pCR in patients with HR+,HER-2-positive breast cancer treated with neoadjuvant docetaxel,carboplatin,trastuzumab,and pertuzumab (TCHP) +/- estrogen deprivation:NRG Oncology/NSABP B-52［J］.Cancer Research,2017,77(4 Supplement):S3-06.
［13］Li J,Z Shao,B Xu,et al.Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER-2-positive breast cancer in China:The Nvwa study［J］.Medicine (Baltimore),2018,97(21):e10350.
［14］Ellis MJ,VJ Suman,J Hoog,et al.Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer:Results from the american college of surgeons oncology group Z1031 Trial (Alliance)［J］.J Clin Oncol,2017,35(10):1061-1069.
［15］Gradishar WJ,BO Anderson,R Balassanian,et al.Breast cancer,version 4.2017,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2018,16(3):310-320.
［16］Bonifazi M,M Franchi,M Rossi,et al.Long term survival of HER-2-positive early breast cancer treated with trastuzumab-based adjuvant regimen:A large cohort study from clinical practice［J］.Breast,2014,23(5):573-578.
［17］Harbeck N.Advances in targeting HER-2-positive breast cancer［J］.Curr Opin Obstet Gynecol,2018,30(1):55-59.
［18］Krop IE,SB Kim,A González.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER-2-positive advanced breast cancer (TH3RESA):A randomised,open-label,phase 3 trial［J］.Lancet Oncology,2014,15(7):689.
［19］Goss PE,JN Ingle,KI Pritchard,et al.A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer［J］.Journal of Clinical Oncology,2016,34(18_suppl):LBA1.
［20］Goss PE.Extending endocrine therapy in women with hormone receptor-positive breast cancer［J］.Clinical Advances in Hematology & Oncology,2015,13(1):20-22.
［21］Blok EJ,JR Kroep,KE Meershoek-Klein,et al.Optimal duration of extended adjuvant endocrine therapy for early breast cancer,results of the IDEAL trial (BOOG 2006-05)［J］.Journal of the National Cancer Institute,2018,110(1):40-48.
［22］Alqaisi A,L Chen,E Romond,et al.Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER-2) co-expression on breast cancer disease characteristics:Implications for tumor biology and research［J］.Breast Cancer Res Treat,2014,148(2):437-444.
［23］Vici P,L Pizzuti,I Sperduti,et al."Triple positive" early breast cancer:An observational multicenter retrospective analysis of outcome［J］.Oncotarget,2016,7(14):17932-17944.
［24］Seiffert K,B Schmalfeldt,V Muller.Current status of targeted treatment in breast cancer［J］.Dtsch Med Wochenschr,2017,142(22):1669-1675.
［25］Ellis MJ,A Llombartcussac,D Feltl,et al.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:Overall survival analysis from the phase II first study［J］.J Clin Oncol,2015,33(32):3781-3787.
［26］Baselga J,M Campone,M Piccart,et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer［J］.N Engl J Med,2012,366(6):520-529.
［27］Kornblum N,Zhao F,Manola J,et al.Everolimus enhances the efficacy of fulvestrant in ER(+) breast cancer［J］.Cancer Discov,2018,8(6):14.
［28］Sparano JA.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］.J Clin Oncol,2010,28(20):3256.
［29］WANG Y,JIA WJ,RAO NY,et al.Comparison of the early or late use of capecitabine-based regimens for treatment of metastatic breast cancer［J］.Chinese Journal of Cancer Prevention and Treatment,2016,23(15):1006-1010.［汪颖,贾卫娟,饶南燕,等.含卡培他滨方案一线或后线治疗晚期乳腺癌的疗效比较［J］.中华肿瘤防治杂志,2016,23(15):1006-1010.］
［30］Ramakrishna N,S Temin,S Chandarlapaty,et al.Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases:ASCO clinical practice guideline update［J］.J Clin Oncol,2018,14(8):505-507.
［31］Swain SM,SB Kim,J Cortés,et al.Pertuzumab,trastuzumab,and docetaxel for HER-2-positive metastatic breast cancer (CLEOPATRA study):Overall survival results from a randomised,double-blind,placebo-controlled,phase 3 study［J］.Lancet Oncology,2013,14(6):461.
［32］Blackwell KL,HJ Burstein,AM Storniolo,et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer:Final results from the EGF104900 study［J］.J Clin Oncol,2012,30(21):2585-2592.
［33］Gianni L,T Pienkowski,YH Im,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER-2-positive breast cancer (NeoSphere):A randomised multicentre,open-label,phase 2 trial［J］.Lancet Oncology,2012,13(1):25-32.
［34］Gianni L,G Bisagni,M Colleoni,et al.Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER-2-positive,ER-positive breast cancer (NA-PHER-2):An exploratory,open-label,phase 2 study［J］.Lancet Oncol,2018,19(2):249-256.